IsojacareubinCAS# 50597-93-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 50597-93-8 | SDF | Download SDF |
PubChem ID | 9996463 | Appearance | Powder |
Formula | C18H14O6 | M.Wt | 326.31 |
Type of Compound | Xanthones | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 6,10,11-trihydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7-one | ||
SMILES | CC1(C=CC2=C3C(=C(C=C2O1)O)C(=O)C4=C(O3)C(=C(C=C4)O)O)C | ||
Standard InChIKey | FSTNFJKGRSHPBO-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H14O6/c1-18(2)6-5-8-12(24-18)7-11(20)13-14(21)9-3-4-10(19)15(22)17(9)23-16(8)13/h3-7,19-20,22H,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Isojacareubin is a potent inhibitor of protein kinase C (PKC), suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo, thus, it as a promising lead compound for the development of new antihepatoma agents. 2. Isojacareubin displays potent activity against H. pylori HP40 clinical isolate with MIC 23.9 uM, which is approximately two times greater than that of the standard drug amoxicillin. |
Targets | PKC | MAPK | Antifection |
Isojacareubin Dilution Calculator
Isojacareubin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0646 mL | 15.3229 mL | 30.6457 mL | 61.2914 mL | 76.6143 mL |
5 mM | 0.6129 mL | 3.0646 mL | 6.1291 mL | 12.2583 mL | 15.3229 mL |
10 mM | 0.3065 mL | 1.5323 mL | 3.0646 mL | 6.1291 mL | 7.6614 mL |
50 mM | 0.0613 mL | 0.3065 mL | 0.6129 mL | 1.2258 mL | 1.5323 mL |
100 mM | 0.0306 mL | 0.1532 mL | 0.3065 mL | 0.6129 mL | 0.7661 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Columbianadin
Catalog No.:BCN1275
CAS No.:5058-13-9
- Fenspiride HCl
Catalog No.:BCC4659
CAS No.:5053-08-7
- 3-(Carboxymethylamino)propanoic acid
Catalog No.:BCN1791
CAS No.:505-72-6
- Homopiperazine
Catalog No.:BCC8995
CAS No.:505-66-8
- Araneosol
Catalog No.:BCN5613
CAS No.:50461-86-4
- GW441756
Catalog No.:BCC5093
CAS No.:504433-23-2
- Methyl 2alpha-hydroxyhardwickiate
Catalog No.:BCN7595
CAS No.:50428-93-8
- 1,5,6-Trihydroxyxanthone
Catalog No.:BCN7642
CAS No.:5042-03-5
- Isorhamnetin-3-O-beta-D-Glucoside
Catalog No.:BCN1247
CAS No.:5041-82-7
- Isoliquiritin
Catalog No.:BCN5945
CAS No.:5041-81-6
- Juglanin
Catalog No.:BCN6505
CAS No.:5041-67-8
- 3-Nitropropionic acid
Catalog No.:BCC6303
CAS No.:504-88-1
- Arachidonic acid
Catalog No.:BCN2215
CAS No.:506-32-1
- Nervonic acid
Catalog No.:BCN8374
CAS No.:506-37-6
- Octacosanoic Acid
Catalog No.:BCN5395
CAS No.:506-48-9
- Niranthin
Catalog No.:BCN5614
CAS No.:50656-77-4
- Alkaloid KD1
Catalog No.:BCN1898
CAS No.:50656-87-6
- Alkaloid C
Catalog No.:BCN1897
CAS No.:50656-88-7
- Vandrikidine
Catalog No.:BCN5615
CAS No.:50656-92-3
- Chasmanine
Catalog No.:BCN5409
CAS No.:5066-78-4
- Terfenadine
Catalog No.:BCC3866
CAS No.:50679-08-8
- Boc-Cys(Bzl)-OH
Catalog No.:BCC3376
CAS No.:5068-28-0
- Borneol
Catalog No.:BCN4964
CAS No.:507-70-0
- Pennogenin
Catalog No.:BCN2839
CAS No.:507-89-1
Anti-Helicobacter pylori xanthones of Garcinia fusca.[Pubmed:24155023]
Arch Pharm Res. 2014 Aug;37(8):972-7.
A new geranylated xanthone derivative, fuscaxanthone I (1), along with nine xanthones (2-9 and 11), a biphenyl (10) and three biflavonoids (12-14) were isolated from the roots of Garcinia fusca Pierre. Compounds 8, 10 and 11-14 were reported from this plant species for the first time. Their structures were elucidated by spectroscopic analyses, including 1D- and 2D-NMR and MS. The isolated compounds were evaluated for antibacterial activity against Helicobacter pylori. Cowaxanthone (5) and fukugiside (14) exhibited stronger inhibitory activity against H. pylori DMST reference strain at MICs 4.6 and 10.8 muM, respectively, than that of the control metronidazole. Isojacareubin (8) displayed the most potent activity against H. pylori HP40 clinical isolate with MIC 23.9 muM, which was approximately two times greater than that of the standard drug amoxicillin.
Isojacareubin from the Chinese herb Hypericum japonicum: potent antibacterial and synergistic effects on clinical methicillin-resistant Staphylococcus aureus (MRSA).[Pubmed:22942699]
Int J Mol Sci. 2012;13(7):8210-8.
Through bioassay-guided fractionation of the extracts from the aerial parts of the Chinese herb Hypericum japonicum Thunb. Murray, Isojacareubin (ISJ) was characterized as a potent antibacterial compound against the clinical methicillin-resistant Staphylococcus aureus (MRSA). The broth microdilution assay was used to determine the minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of ISJ alone. The results showed that its MICs/MBCs ranged from 4/16 to 16/64 mug/mL, with the concentrations required to inhibit or kill 50% of the strains (MIC(50)/MBC(50)) at 8/16 mug/mL. Synergistic evaluations of this compound with four conventional antibacterial agents representing different types were performed by the chequerboard and time-kill tests. The chequerboard method showed significant synergy effects when ISJ was combined with Ceftazidime (CAZ), Levofloxacin (LEV) and Ampicillin (AMP), with the values of 50% of the fractional inhibitory concentration indices (FICI(50)) at 0.25, 0.37 and 0.37, respectively. Combined bactericidal activities were also observed in the time-kill dynamic assay. The results showed the ability of ISJ to reduce MRSA viable counts by log(10)CFU/mL at 24 h of incubation at a concentration of 1 x MIC were 1.5 (LEV, additivity), 0.92 (CAZ, indifference) and 0.82 (AMP, indifference), respectively. These in vitro anti-MRSA activities of ISJ alone and its synergy with conventional antibacterial agents demonstrated that ISJ enhanced their efficacy, which is of potential use for single and combinatory therapy of patients infected with MRSA.
Bioassay-guided isolation of prenylated xanthones and polycyclic acylphloroglucinols from the leaves of Garcinia nujiangensis.[Pubmed:22871217]
J Nat Prod. 2012 Aug 24;75(8):1459-64.
Bioassay-guided fractionation of the acetone extract of the leaves of Garcinia nujiangensis resulted in the isolation of two new prenylated xanthones, nujiangexanthones A (1) and B (2), three new polycyclic polyprenylated acylphloroglucinols, nujiangefolins A-C (3-5), and 10 known related analogues. The structures of compounds 1-5 were elucidated by interpretation of their spectroscopic data. Compounds 3 and 4 are unusual polycyclic polyprenylated acylphloroglucinols in which the enol hydroxy group forms a six-membered ring with a benzene ring carbon. The compounds isolated were evaluated for their cytotoxic effects against 11 cancer cell lines and immortalized MIHA normal liver cells, and the test substances demonstrated selectivity toward the cancer cells. Isojacareubin (6) was found to be the most potent cytotoxic compound of those tested.
Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo.[Pubmed:26245668]
Sci Rep. 2015 Aug 6;5:12889.
Targeted inhibition of protein kinase C (PKC) inhibits hepatocellular carcinoma (HCC) proliferation and metastasis. We previously reported the cytotoxicity of a series of synthetic phenyl-substituted polyoxygenated xanthone derivatives against human HCC. In the current study, the most potent natural product, Isojacareubin (ISJ), was synthesized, and its cellular-level antihepatoma activities were evaluated. ISJ significantly inhibited cell proliferation and was highly selective for HCC cells in comparison to nonmalignant QSG-7701 hepatocytes. Moreover, ISJ exhibited pro-apoptotic effects on HepG2 hepatoma cells, as well as impaired HepG2 cell migration and invasion. Furthermore, ISJ was a potent inhibitor of PKC, with differential actions against various PKC isotypes. ISJ selectively inhibited the expression of aPKC (PKCzeta) in the cytosol and the translocation of cytosolic PKCzeta to membrane site. ISJ also directly interacted with cPKC (PKCalpha) and nPKC (PKCdelta, PKCepsilon and PKCmu) and thereby inhibited the early response of major MAPK phosphorylation and the late response of HCC cell invasion and proliferation. In a hepatoma xenograft model, ISJ pretreatment resulted in significant antihepatoma activity in vivo. These findings identify ISJ as a promising lead compound for the development of new antihepatoma agents and may guide the search for additional selective PKC inhibitors.